Radio-induced apoptosis is mediated by the activation of tumor protein p53, Bax and caspases. The purpose of this study was to investigate the early activation of this pathway in men receiving in vivo irradiation immediately before radical prostatectomy for locally advanced prostate cancer. We also investigated cell proliferation index (Ki-67), proto-oncogene (p53) and anti-apoptotic protein (Bcl-2) levels as potential predictive factors. We selected a homogeneous sample of 20 patients with locally advanced prostate cancer and candidate to radical prostatectomy. To assess the apoptotic pathways, Bax, is studied through immunofluorescence assay, before and after 12 Gy single dose intraoperative radiotherapy (IORT) to the prostate, on bioptic samples and on surgical specimens. Moreover, before and after IORT, Bcl-2, p53, and Ki-67 were also detected through immunohistochemistry. A count of positive Bax spots for immunofluorescence was performed on tumor cells, prostatic intraepithelial neoplasia (PIN), and healthy tissue areas before and after IORT. We also analyzed Caspases 3 and 9 expressions after IORT. Before IORT, Bcl-2 mean value in neoplastic cells was 2.23% ± 1.95, mean Ki-67 in neoplastic area was 4.5% ± 3.8, and p53 was 22.5% ± 6.8. After IORT, Bcl-2 mean value in neoplastic cells was 8.85 ± 8.92%, Ki-67 in neoplastic area was 7.8 ± 6.09%, and p53 was 24.9 ± 26.4%. After the irradiation, healthy areas expressed significantly lower levels of Bax (2.81 ± 1.69%) with respect to neoplastic cells (p < 0.0001), while in PIN areas, Bax positive cells were significantly more present than in neoplastic areas (p = 0.0001). At statistical analysis, it was observed that cancer cells with Ki-67 ≥ 8% had a trend toward greater expression of Bax (p = 0.0641). We observed an increase of Bcl-2 expression after IORT in neoplastic areas (p = 0.0041). Biopsy specimens with p53 ≥ 18% and Ki-67 ≥ 8% had worse post-operative staging with extracapsular invasion (p = 0.04 for both parameters) and nodal positivity (p = 0.04 for p53 and p = 0.0001 at pathology for ki-67). No correlation between IORT and Caspases activation was noted. In conclusion, after 12 Gy IORT, Bax was overexpressed in tumor and PIN cells. Pre-operative Ki-67 and p53 definition could be used in future studies to predict patients with worse pathological stage, while Bcl-2 activation after IORT might be a predictive factor for loco-regional failure.
The aim of this study was to assess the effects of psychotherapy with music intervention (PMI) on anxiety, depression, redox status, and inflammation in breast cancer patients undergoing radiotherapy (RT). This monocentric randomized clinical trial recruited 60 patients who had a breast cancer operation and were undergoing postoperative RT. Eligible patients were randomized (1:1) in two groups: the control group (CG) received treatment as usual (n = 30), i.e., RT alone; the intervention group (PMI) received RT and psychotherapy with music intervention (n = 30), which was delivered in a group setting. Five patients were excluded after randomization. Assessments were performed at baseline (T0), at the end of RT (T1), and three months after the end of RT (T2). The main objectives of the study were the assessment of anxiety/depression, plasma glutathione (GSH), and thiobarbituric acid reactive substances (TBARS) in the two arms of the study. Our findings revealed a positive effect of PMI on anxiety, depression, resilience, and quality of life. Furthermore, a positive effect of PMI on redox status was found for the first time. Thus, in the PMI group, we found a significant increase of GSH (mean change 2.2 95%, CI 0.7 to 3.7) and a significant reduction of TBARS (mean change −1.1 95%, CI −1.8 to −0.3) at T2 vs. T0.
Introduction. The clinical course of Coronavirus Disease 2019 (COVID-19) is highly heterogenous, ranging from asymptomatic to fatal forms. The identification of clinical and laboratory predictors of poor prognosis may assist clinicians in monitoring strategies and therapeutic decisions. Materials and Methods. In this study, we retrospectively assessed the prognostic value of a simple tool, the complete blood count, on a cohort of 664 patients ( 260; 39%, median age 70 (56-81) years) hospitalized for COVID-19 in Northern Italy. We collected demographic data along with complete blood cell count; moreover, the outcome of the hospital in-stay was recorded. Results. At data cut-off, 221/664 patients (33.3%) had died and 453/664 (66.7%) had been discharged. Red cell distribution width (RDW) ( 10.4; ), neutrophil-to-lymphocyte (NL) ratio ( 7.6; ), and platelet count ( 5.39; ), along with age ( 87.6; ) and gender ( 17.3; ), accurately predicted in-hospital mortality. Hemoglobin levels were not associated with mortality. We also identified the best cut-off for mortality prediction: a was characterized by an odds ratio for in-hospital (2.40-4.82), while the OR for a
Prof. Dr. Marco Krengli is Full Professor (Professore Ordinario) of Radiotherapy at the University of Padova’s Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG). Prior to 2022, he held the same professorship at the University of Eastern Piedmont’s Department of Translational Medicine.
He currently serves as Dean of the Medical School, Director of the Radiation Oncology Division, and Director of the Department of Specialized Medicine and Oncology at Novara’s Azienda Ospedaliero-Universitaria “Maggiore della Carità.” A specialist in Oncology, Radiotherapy, and Radiology, he was a Research Fellow at Harvard University from 1995 to 1996.
His research focuses on EORTC studies (brain and head–neck tumors), prognostic factors in head–neck cancer, proton therapy (skull base tumors and retinoblastoma), and CT/MRI/SPECT image integration for radiotherapy planning and intraoperative radiation therapy.
With an H-index of 37, Prof. Krengli has published over 200 scientific journal articles, more than 400 conference abstracts, and 18 book chapters. He is a member of ESTRO, ASTRO, EORTC, PTCOG, ISIORT, AIRO, AIRB, FONCAM, and SIB.
Prof. Dr. Marco Krengli is Full Professor (Professore Ordinario) of Radiotherapy at the University of Padova’s Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG). Prior to 2022, he held the same professorship at the University of Eastern Piedmont’s Department of Translational Medicine.
He currently serves as Dean of the Medical School, Director of the Radiation Oncology Division, and Director of the Department of Specialized Medicine and Oncology at Novara’s Azienda Ospedaliero-Universitaria “Maggiore della Carità.” A specialist in Oncology, Radiotherapy, and Radiology, he was a Research Fellow at Harvard University from 1995 to 1996.
His research focuses on EORTC studies (brain and head–neck tumors), prognostic factors in head–neck cancer, proton therapy (skull base tumors and retinoblastoma), and CT/MRI/SPECT image integration for radiotherapy planning and intraoperative radiation therapy.
With an H-index of 37, Prof. Krengli has published over 200 scientific journal articles, more than 400 conference abstracts, and 18 book chapters. He is a member of ESTRO, ASTRO, EORTC, PTCOG, ISIORT, AIRO, AIRB, FONCAM, and SIB.